TORPRAZOLE pantoprazole (as sodium sesquihydrate) 40 mg enteric coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

torprazole pantoprazole (as sodium sesquihydrate) 40 mg enteric coated tablet blister pack

torrent australasia pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.1 mg (equivalent: pantoprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: mannitol; crospovidone; sodium carbonate; hyprolose; calcium stearate; hypromellose; titanium dioxide; iron oxide yellow; propylene glycol; triethyl citrate; purified talc; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide red; iron oxide black; ethanol; shellac; sulfuric acid - symptomatic improvement and healing of the following gastrointestinal diseases which require a reduction in acid secretion. duodenal ulcer. gastric ulcer. gastroesophageal reflux disease (gord). symptomatic gord: the treatment of heartburn and other symptoms associated with gord. reflux oesophagitis. gastrointestinal lesions refractory to h 2 -blockers. zollinger-ellison syndrome. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective nsaids in increased risk patients with a need for continuous nonselective nsaid treatment

TORPRAZOLE pantoprazole (as sodium sesquihydrate) 20 mg enteric coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

torprazole pantoprazole (as sodium sesquihydrate) 20 mg enteric coated tablet blister pack

torrent australasia pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.55 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: mannitol; crospovidone; sodium carbonate; hyprolose; calcium stearate; hypromellose; titanium dioxide; iron oxide yellow; propylene glycol; triethyl citrate; purified talc; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide red; iron oxide black; ethanol; shellac; sulfuric acid - symptomatic improvement and healing of the following gastrointestinal diseases which require a reduction in acid secretion. duodenal ulcer. gastric ulcer. gastroesophageal reflux disease (gord). symptomatic gord: the treatment of heartburn and other symptoms associated with gord. reflux oesophagitis. gastrointestinal lesions refractory to h 2 -blockers. zollinger-ellison syndrome. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective nsaids in increased risk patients with a need for continuous nonselective nsaid treatment

TORPRAZOLE pantoprazole (as sodium sesquihydrate) 20 mg enteric coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

torprazole pantoprazole (as sodium sesquihydrate) 20 mg enteric coated tablet bottle

torrent australasia pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.55 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: mannitol; crospovidone; sodium carbonate; hyprolose; calcium stearate; hypromellose; titanium dioxide; iron oxide yellow; propylene glycol; triethyl citrate; purified talc; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; butan-1-ol; isopropyl alcohol; iron oxide red; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - symptomatic improvement and healing of the following gastrointestinal diseases which require a reduction in acid secretion. duodenal ulcer. gastric ulcer. gastroesophageal reflux disease (gord). symptomatic gord: the treatment of heartburn and other symptoms associated with gord. reflux oesophagitis. gastrointestinal lesions refractory to h 2 -blockers. zollinger-ellison syndrome. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective nsaids in increased risk patients with a need for continuous nonselective nsaid treatment

TORPRAZOLE pantoprazole (as sodium sesquihydrate) 40 mg enteric coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

torprazole pantoprazole (as sodium sesquihydrate) 40 mg enteric coated tablet bottle

torrent australasia pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.1 mg (equivalent: pantoprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: mannitol; crospovidone; sodium carbonate; hyprolose; calcium stearate; hypromellose; titanium dioxide; iron oxide yellow; propylene glycol; triethyl citrate; purified talc; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; butan-1-ol; isopropyl alcohol; iron oxide red; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - symptomatic improvement and healing of the following gastrointestinal diseases which require a reduction in acid secretion. duodenal ulcer. gastric ulcer. gastroesophageal reflux disease (gord). symptomatic gord: the treatment of heartburn and other symptoms associated with gord. reflux oesophagitis. gastrointestinal lesions refractory to h 2 -blockers. zollinger-ellison syndrome. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective nsaids in increased risk patients with a need for continuous nonselective nsaid treatment